Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.
Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma.
Researchers sought to determine whether giving maintenance ixazomib to patients with multiple myeloma who undergo allogeneic hematopoietic stem cell transplantation would have a clinical benefit.
Researchers sought to determine whether the combination of MGTA-145 and plerixafor would be effective for HSC mobilization for autologous transplant in patients with multiple myeloma.
Researchers sought to determine whether idecabtagene vicleucel would have durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
Researchers sought to determine whether selinexor could be safely combined with pomalidomide and dexamethasone in heavily pretreated patients with multiple myeloma.
The additional strengths are intended to increase patient compliance and reduce pill burden.
The approval is supported by data from the multicenter, randomized, open-label phase 3 IKEMA trial.
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.
Progression-free, three-year overall survival similar for lenalidomide maintenance regimen without dexamethasone
